Proguanil-sulphonamide for malaria prophylaxis. 1990

J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand.

There are few safe, effective chemoprophylactic regimens for preventing Plasmodium falciparum infection in south-east Asia. In two randomized placebo-controlled trials, combinations of proguanil and sulphonamide were tested for chemoprophylactic activity in schoolchildren, aged 6-15 years, living near the Thai-Burmese border. Proguanil at an equivalent adult dose of 200 mg/d was combined with sulphafurazole (= sulfisoxazole) at 25 mg/kg/d or sulphamethoxazole at 25 and 10 mg/kg/d. Combinations of daily proguanil/sulphafurazole and proguanil/sulphamethoxazole were equally effective (greater than 75%) against both falciparum and vivax malaria when the sulphonamide component was used at 25 mg/kg/d. Proguanil and sulphamethoxazole at 10 mg/kg/d was ineffective. Approximately 1% of the children had sulphonamide-related skin rashes which resolved when treatment stopped. Proguanil/sulphonamide is a possible alternative chemoprophylactic regimen in areas with multiple drug-resistant P. falciparum.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D008297 Male Males
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D010966 Plasmodium vivax A protozoan parasite that causes vivax malaria (MALARIA, VIVAX). This species is found almost everywhere malaria is endemic and is the only one that has a range extending into the temperate regions. Plasmodium vivaxs,vivax, Plasmodium
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002727 Proguanil A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent. Chlorguanid,Chloroguanide,Bigumal,Chloriguane,Chloroguanide Hydrochloride,Paludrin,Paludrine,Proguanil Hydrochloride,Hydrochloride, Chloroguanide,Hydrochloride, Proguanil
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D005260 Female Females

Related Publications

J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
May 1983, Lancet (London, England),
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
April 1983, Lancet (London, England),
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
July 1987, The Journal of infectious diseases,
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
March 1983, Lancet (London, England),
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
May 1999, Journal of travel medicine,
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
October 2001, Drug and therapeutics bulletin,
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
September 2003, The Annals of pharmacotherapy,
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
December 2005, Expert review of anti-infective therapy,
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
March 2017, Journal of travel medicine,
J J Karwacki, and G D Shanks, and N Limsomwong, and P Singharaj
January 1990, Lancet (London, England),
Copied contents to your clipboard!